

## AUTHOR INDEX

- Bourbonniere, M., 51  
 Calarese, P., 152  
 Carper, E., 203  
 Cash, J.C., 242  
 Crighton, M.H., 3  
 Dest, V.M., 249  
 Dow, K.H., 129  
 Duggleby, W., 58  
 Gemmill, R., 90  
 Given, B., 43  
 Gosselin-Aeomb, T.K., 198  
 Greco, K., 10  
 Haas, M.L., 65, 197, 203  
 Hogle, W.P., 212  
 Jenkins, J., 117  
 Kagan, S.H., 1  
 Lacasse, C., 20  
 Levine, A.M., 80  
 Liebenguth, P., 257  
 Long, J., 97  
 Lyder, C.H., 178  
 Manson, S.D., 73  
 McNees, P., 129, 130  
 McQuestion, M., 163  
 Moore-Higgs, G.J., 233  
 Morse, L., 152  
 Payne, J.K., 31  
 Puppione, A.A., 3  
 Raudonis, B.M., 58  
 Reiner, A., 20  
 Rogers, B.B., 67  
 Seaman, S., 185  
 Sherwood, P.R., 43  
 Steffey-Stacy, E.C., 221  
 Steinberg, S.K., 65, 107  
 Temple, S.V., 257  
 Toth, P.E., 174  
 Van Cleave, J.H., 51  
 Versea, L., 97  
 Viale, P.H., 144  
 Visovsky, C., 36

## SUBJECT INDEX

- Advanced practice nurses, in radiation oncology, 203–211  
 — during brachytherapy, 208  
 — in consultation, 207  
 — during external beam radiation therapy, 208  
 — during follow-up visits, 208–209  
 — in managing after hours care, 209  
 — in simulation, 207–208
- Bexxar, in radioimmunotherapy for non-Hodgkin's lymphoma, 262–264
- Brachytherapy, 217  
 — for early stage breast cancer  
     — interstitial brachytherapy, 236–237  
     — intracavitary brachytherapy, 237–238  
 — role of advanced practice nurses during, 208
- Breast cancer, early stage, radiation therapy options for, 233–241  
 — considerations for nursing care, 240  
 — partial breast irradiation, 235–236  
     — interstitial brachytherapy, 236–237  
     — intracavitary brachytherapy, 237–238  
     — intraoperative radiotherapy, 238  
     — other techniques, 240  
     — 3-D conformal radiotherapy, 239–240  
     — surgery and, 234  
     — whole-breast radiotherapy, 235
- Cancer survivorship, and QOL, effects of radioprotectants on, 249–255  
 — head and neck cancers, 251–253  
 — history of, 250  
 — lung cancer, 253–254  
 — mechanism of action, 250–251  
 — pelvic cancers, 254  
 — utilization in clinical practice, 251
- CD20 antigens, in radioimmunotherapy for non-Hodgkin's lymphoma, 258
- Combined modality therapy, nurse's role in, 199–200  
 — safety issues and practice implications, 201
- Consultations, role of advanced practice nurses in, 207
- CyberKnife radiosurgery, image-guided, 217
- External beam radiation therapy, role of advanced practice nurses during, 208
- Frameless image-guided stereotactic radiosurgery, 221–232  
 — historical perspectives  
     — CyberKnife, 222–223
- definition, 221  
 early radiosurgery, 222  
 stereotactic frames, 221–222
- nurse's role in, 227–230
- trials and processes  
 — clinical data, 223–224  
 — procedural components, 224–227
- Head and neck cancer, effects of radioprotectants on QOL and survivorship in, 251–253
- Image-guided CyberKnife radiosurgery, 217
- Image-guided radiotherapy, 216–217
- Image-guided stereotactic radiosurgery, frameless, 221–232  
 — historical perspectives  
     — CyberKnife, 222–223  
     — definition, 221  
     — early radiosurgery, 222  
     — stereotactic frames, 221–222  
 — nurse's role in, 227–230  
 — trials and processes  
     — clinical data, 223–224  
     — procedural components, 224–227
- Infusional toxicities, during radioimmunotherapy for non-Hodgkin's lymphoma, 261
- Intensity modulated radiation therapy, 216, 242–248  
 — advantages of, 242–243  
 — clinical applications of, 246–247  
 — implications for nursing practice, 247  
 — planning and delivery, 243–346  
     — inverse treatment planning, 244  
     — patient set-up and treatment delivery, 244–246  
     — simulation, 244
- Interstitial brachytherapy, for early stage breast cancer, 236–237
- Intracavitary brachytherapy, for early stage breast cancer, 237–238
- Intraoperative radiation therapy, 217  
 — for early stage breast cancer, 238
- Inverse treatment planning, in Intensity modulated radiation therapy, 244
- Irradiation, partial breast, for early stage breast cancer, 235–236  
 — interstitial brachytherapy, 236–237  
 — intracavitary brachytherapy, 237–238  
 — intraoperative radiotherapy, 238  
 — other techniques, 240

- 3-D conformal radiotherapy, 239–240
- Lung cancer, effects of radioprotectants on QOL and survivorship in, 253–254
- Lymphoma, non-Hodgkin's. *See* Non-Hodgkin's lymphoma
- Monoclonal antibodies, in radioimmunotherapy for non-Hodgkin's lymphoma, 258
- Non-Hodgkin's lymphoma, radioimmunotherapy for, 257–265
- Bexxar regimen, 262–264
  - CD20 antigens, 258
  - monoclonal antibodies, 258
  - post therapy follow-up, 261–262
  - pretherapy evaluation, 259–261
  - rituximab, 258–259
  - toxicity during infusion, 261
  - Zevalin regimen, 264
- Nurse's role, in radiation oncology, 198–202
- advanced practice nurses, 203–211
  - during brachytherapy, 208
  - in consultation, 207
  - during external beam radiation therapy, 208
  - during follow-up visits, 208–209
  - in managing after hours care, 209
  - in simulation, 207–208
  - in combined modality therapy, 199–200
  - safety issues and practice implications, 201
  - evolution of, 198–199
  - in frameless image-guided stereotactic radiosurgery, 227–230
- Oncology, radiation. *See* Radiation oncology
- Partial breast irradiation, for early stage breast cancer, 235–236
- interstitial brachytherapy, 236–237
  - intracavitary brachytherapy, 237–238
  - intraoperative radiotherapy, 238
  - other techniques, 240
  - 3-D conformal radiotherapy, 239–240
- Pelvic cancer, effects of radioprotectants on QOL and survivorship in, 254
- Quality of life (QOL), and cancer survivorship, effects of radioprotectants on, 249–255
- head and neck cancers, 251–253
  - history of, 250
  - lung cancer, 253–254
  - mechanism of action, 250–251
  - pelvic cancers, 254
  - utilization in clinical practice, 251
- Radiation oncology, 197
- advanced practice nurses, 203–211
  - during brachytherapy, 208
  - in consultation, 207
  - during external beam radiation therapy, 208
  - during follow-up visits, 208–209
  - in managing after hours care, 209
  - in simulation, 207–208
  - nurse's role, 198–201
  - in combined modality therapy, 199–201
- evolution of, 198–199
- Radiation therapy
- acute effects of, 218
  - cellular response to, 213–214
  - external beam, role of advanced practice nurses during, 208
  - long-term survivorship issues, 218–219
  - options for early stage breast cancer, 233–241
  - considerations for nursing care, 240
  - partial breast irradiation, 235–240
  - surgery and, 234
  - whole-breast radiotherapy, 235
- treatment modalities, 214–216
- brachytherapy, 217
  - image-guided CyberKnife radiosurgery, 217
  - image-guided radiotherapy, 216–217
  - intensity modulated radiation therapy, 216, 242–248
  - intraoperative radiation therapy, 217
  - stereotactic radiosurgery, 217
- Radioimmunotherapy, for non-Hodgkin's lymphoma, 257–265
- Bexxar regimen, 262–264
  - CD20 antigens, 258
  - monoclonal antibodies, 258
  - post therapy follow-up, 261–262
  - pretherapy evaluation, 259–261
  - rituximab, 258–259
  - toxicity during infusion, 261
  - Zevalin regimen, 264
- Radioprotectants, effects on QOL and survivorship, 249–255
- head and neck cancers, 251–253
  - history of, 250
  - lung cancer, 253–254
  - mechanism of action, 250–251
  - pelvic cancers, 254
  - utilization in clinical practice, 251
- Radiosurgery
- image-guided CyberKnife, 217
  - stereotactic, 217
  - frameless image-guided, 221–232
- Rituximab, in radioimmunotherapy for non-Hodgkin's lymphoma, 258–259
- Simulation
- in intensity modulated radiation therapy, 244
  - role of advanced practice nurses in, 207–208
- Stereotactic radiosurgery, 217
- frameless image-guided, 221–232
  - historical perspectives, 221–223
  - nurse's role in, 227–230
  - trials and processes, 223–227
- Surgery, for early stage breast cancer, 234
- Survivorship. *See* Cancer survivorship
- 3-D conformal radiotherapy, for early stage breast cancer, 239–240
- Toxicity, infusional, during radioimmunotherapy for non-Hodgkin's lymphoma, 261
- Whole-breast radiotherapy, for early stage breast cancer, 235
- Zevalin, in radioimmunotherapy for non-Hodgkin's lymphoma, 264

